Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients

Area of Science:

• * Cardiovascular Pharmacology
• * Infectious Diseases
• * Molecular Biology

Background:

• * Coronavirus disease 2019 (COVID-19) has caused significant global mortality, with no definitive treatments available.
• * Existing therapeutic strategies have shown limited efficacy in clinical trials.
• * The pathophysiology of COVID-19 involves complex interactions between multiple physiological systems.

Purpose of the Study:

• * To investigate the interplay between the Adrenergic system and the renin-angiotensin-aldosterone system (RAAS) in the context of COVID-19.
• * To propose a novel pathophysiological mechanism for COVID-19, termed the "ARAS loop."
• * To explore the potential of beta-adrenergic blockers as a therapeutic intervention for COVID-19.

Main Methods:

• * Review and analysis of existing literature on the Adrenergic system, RAAS, ACE2, and SARS-CoV-2.
• * Hypothetical modeling of the proposed "ARAS loop" in COVID-19 pathogenesis.
• * In silico or in vitro studies to assess the impact of beta-adrenergic blockers on ACE2 and CD147 expression.

Main Results:

• * A proposed "ARAS loop" (Adrenergic system-RAAS-ACE2-SARS-CoV-2) may underlie COVID-19 hyperactivation.
• * Beta-adrenergic blockers may inhibit SARS-CoV-2 cellular entry by downregulating ACE2 and CD147 receptors.
• * This mechanism suggests a potential reduction in COVID-19-related morbidity and mortality.

Conclusions:

• * The ARAS loop presents a novel hypothesis for COVID-19 pathophysiology.
• * Beta-adrenergic blockers show promise as a potential treatment to mitigate COVID-19 severity.
• * Further clinical trials are warranted to validate the efficacy of beta-adrenergic blockers in COVID-19 patients.